long intergenic non-protein coding RNA 970Genealiases: []
Q-omics provides the consensus-scored LINC00970 profile across patient tissues and cancer cell-line models. LINC00970 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SARC. Among the 18 cancer types available for tumor–normal comparison, LINC00970 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, LINC00970 RNA expression shows 7,300 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight SARC, KIRP, and CCRCC as cancer lineages where LINC00970 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00970 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00970 survival associations across molecular data types. LINC00970 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00970 RNA expression–survival associations across cancer types. High LINC00970 expression shows unfavorable associations in SARC and OV, but favorable associations in ACC, HNSC, KIRC and BLCA. The SARC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SARC as the clearest survival context for LINC00970 RNA expression.
This table summarizes LINC00970 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00970. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00970 shows lower tumor expression in KIRP, KIRC and KICH and higher tumor expression in BRCA, LUAD and LUSC. The KIRP box plot shows higher LINC00970 RNA expression in normal versus tumor tissue (log2 FC = −0.537, t-test p < 0.001).
This table shows molecular features associated with LINC00970 in patient tissues and cancer cell lines. In patient samples, LINC00970 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
